Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $26.3750.
Several analysts recently weighed in on KURA shares. Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. Lake Street Capital started coverage on Kura Oncology in a research note on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price target on the stock. UBS Group restated a “buy” rating and issued a $15.00 price target (down from $16.00) on shares of Kura Oncology in a research note on Friday, March 13th. Finally, Mizuho lowered their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 24th.
Check Out Our Latest Research Report on Kura Oncology
Kura Oncology Stock Performance
Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.05. The company had revenue of $18.27 million for the quarter, compared to the consensus estimate of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. On average, equities research analysts predict that Kura Oncology will post -3.23 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Kura Oncology
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Kura Oncology by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares in the last quarter. Strs Ohio bought a new position in Kura Oncology in the 1st quarter valued at approximately $143,000. Legal & General Group Plc lifted its position in Kura Oncology by 35.1% in the 2nd quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after acquiring an additional 18,930 shares in the last quarter. Rhumbline Advisers lifted its position in Kura Oncology by 13.0% in the 2nd quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after acquiring an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Kura Oncology by 244.5% in the 2nd quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after acquiring an additional 165,189 shares in the last quarter.
Kura Oncology Company Profile
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Featured Stories
- Five stocks we like better than Kura Oncology
- Freight Boom: The Hormuz Blockade Payday
- The Palantir Paradox—Record Numbers and a Stock That Won’t Cooperate
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.gif){kind=logo}
